Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Commercial Companies Coronavirus COVID-19

Analyst Predicts $20bn COVID Vaccines Market In 2021

Pfizer Expected To Take Early Lead

Executive Summary

Analysts have taken a first stab at predicting the size of the COVID-19 vaccine market – in which Pfizer and Moderna are likely to start strong, but could give way to other big players.

You may also be interested in...



Coronavirus Update: Sanofi And GSK’s ‘Tortoise’ Joins Hares In Vaccine Race

Initial results from the study are expected in early December 2020, which would allow the start of a Phase III trial before the end of the year.

GSK-Partnered Alector Hit By Renewed Dementia Skepticism

Investors were spooked by mixed results from Alector’s lead candidate but the company’s CEO hit out at ‘hype’ around the biomarker  neurofilament light chain.

AstraZeneca’s Soriot Dismisses Any Pfizer Vaccine ‘Envy’ Amid Buoyant Q2 Results

The UK company has raised its forecasts for 2021 after a better-than-expected Q2, even though Vaxzevria remains a very mixed blessing.

Table

View full table

Topics

Related Companies

Tags:
Commercial Companies Coronavirus COVID-19
UsernamePublicRestriction

Register

SC142804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

;